Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

Genome editing group Intellia Therapeutics has appointed Moncef Slaoui and Frank Verwiel to join its board of directors at a time when the board is establishing a Science and Technology Committee, which will be chaired by Slaoui.

Slaoui (pictured right) recently retired as chairman of vaccines at GlaxoSmithKline (GSK), where he also served on the company’s executive team and board of directors for eleven years.

During his 30-year career at GSK, he worked on drug discovery and development, business development, new product development and commercial organisations.

He was also chairman of GSK’s global R&D organisation for eight years and led the global integration of Novartis’ vaccine unit into GSK.

Additionally, Dr Frank Verwiel (pictured left) joins the group’s board of directors after serving ObsEva SA, a biopharmaceutical company focussed on women’s reproductive health.

He has held numerous leadership roles including president and CEO of Aptalis Pharma prior to its acquisition by Forest Laboratories.

Verwiel has also served at Merck & Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the Netherlands.

Perry Karsen, chair of the board of directors at Intellia Therapeutics, said: “We are very pleased to welcome Drs Slaoui and Verwiel to our Board of Directors. They bring decades of scientific, operational, business and strategic experience in the pharmaceutical and biotech industries to Intellia.

“We look forward to their guidance as we continue to advance our genome editing technology to patients.”